Drugs & Aging

, Volume 30, Issue 6, pp 429–438

Efficacy and Safety of Insulin Glargine Compared to Other Interventions in Younger and Older Adults: A Pooled Analysis of Nine Open-Label, Randomized Controlled Trials in Patients with Type 2 Diabetes

  • Naushira Pandya
  • Andres DiGenio
  • Ling Gao
  • Meenakshi Patel
Original Research Article

Abstract

Objective

Elderly patients with type 2 diabetes mellitus (T2DM) present therapeutic challenges related to co-morbidities, treatment adherence, and safety. This study examines the efficacy and safety of insulin glargine compared to other glucose-lowering interventions in younger and older adults.

Methods

In this pooled analysis of 24-week data from nine prospective open-label, multicenter, phase 3/4, two-arm, parallel-group, randomized controlled trials, patients with T2DM aged 18–80 years received insulin glargine (used as a basal insulin regimen) or comparators (including rosiglitazone, pioglitazone, insulin lispro, insulin lispro 75/25, NPH insulin, NPH insulin 30/70, and lifestyle/dietary measures). Endpoints included change from baseline to week 24 in: glycated hemoglobin; fasting plasma glucose; body weight; body mass index; insulin dose; incidence of nocturnal, daytime, or any hypoglycemia. Results were stratified by age (<65, ≥65, 65–74, and ≥75 years) and treatment (insulin glargine or comparator).

Results

A total of 2,938 patients were included (2,263 aged <65 years, 675 aged ≥65 years). Similar levels of glycemic control were achieved in both younger (<65 years) and older (≥65 years) patients with T2DM. Insulin glargine was associated with better glycemic control and a reduced incidence of daytime and any hypoglycemia versus comparator interventions in both younger and older T2DM patients.

Conclusion

This analysis suggests that insulin glargine may represent a safe option to improve glycemic control in older patients with T2DM.

References

  1. 1.
    American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35(Suppl 1):S11–63.Google Scholar
  2. 2.
    Resnick HE, Heineman J, Stone R, et al. Diabetes in US nursing homes, 2004. Diabetes Care. 2008;31:287–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Russell LB, Valiyeva E, Roman SH, et al. Hospitalizations, nursing home admissions, and deaths attributable to diabetes. Diabetes Care. 2005;28:1611–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Suh D-C, Kim C-M, Choi I-S, et al. Comorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, 1988 to 1994 to 1999 to 2004. J Am Geriatr Soc. 2008;56:484–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Travis SS, Buchanan RJ, Wang S, et al. Analyses of nursing home residents with diabetes at admission. J Am Med Dir Assoc. 2004;5:320–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Fravel MA, McDanel DL, Ross MB, et al. Special considerations for treatment of type 2 diabetes mellitus in the elderly. Am J Health Syst Pharm. 2011;68:500–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Grossman S. Management of type 2 diabetes mellitus in the elderly: role of the pharmacist in a multidisciplinary health care team. J Multidiscip Healthc. 2011;4:149–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25:245–54.PubMedCrossRefGoogle Scholar
  9. 9.
    Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging. 2004;21:511–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Davies M, Storms F, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Haas LB. Optimizing insulin use in type 2 diabetes: role of basal and prandial insulin in long-term care facilities. J Am Med Dir Assoc. 2007;8:502–10.PubMedCrossRefGoogle Scholar
  12. 12.
    Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009;25:542–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Pandya N, DiGenio A, Patel M. Insulin glargine vs comparators in adults <65 vs ≥65 years of age. Diabetes. 2011;60(Suppl. 1):A610.Google Scholar
  14. 14.
    Patel M, DiGenio A, Pandya N. Pooled analysis reveals greater glycemic control with insulin glargine vs comparators in adults aged 65–74 and ≥75 years. Diabetes 2011;60(Suppl. 1):A617.Google Scholar
  15. 15.
    Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29:554–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med. 2006;23:736–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet. 2008;371:1073–84.PubMedCrossRefGoogle Scholar
  18. 18.
    Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442–51.PubMedCrossRefGoogle Scholar
  21. 21.
    Meneghini LF, Traylor L, Schwartz SL. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. Endocr Pract. 2010;16:588–99.PubMedCrossRefGoogle Scholar
  22. 22.
    Blicklé J-F, Hancu N, Piletic M, et al. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% A1c levels; the TULIP study. Diabetes Obes Metab. 2009;11:379–86.PubMedCrossRefGoogle Scholar
  23. 23.
    California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(5 Suppl Guidelines):S265–80.Google Scholar
  24. 24.
    Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.PubMedCrossRefGoogle Scholar
  25. 25.
    Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRefGoogle Scholar
  26. 26.
    ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.Google Scholar
  27. 27.
    Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–72.Google Scholar
  28. 28.
    Currie CJ, Peter JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.Google Scholar
  30. 30.
    Davis KL, Wei W, Meyers J, et al. A retrospective study of basal insulin analogs in elderly nursing home residents with type-2 diabetes. J Am Geriatr Soc. 2012;60 (Suppl S4):S51.Google Scholar
  31. 31.
    Alam T, Weintraub N, Weinreb J. What is the proper use of hemoglobin monitoring in the elderly? J Am Med Dir Assoc. 2005;6:200–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Akram K, Pedersen-Bjergaard U, Borch-Johnsen K, et al. Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. J Diabetes Complicat. 2006;20:402–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;340:b5444.Google Scholar
  34. 34.
    Schultes B, Baron M, Bremer JP, et al. Reduced awareness of hypoglycaemia in elderly patients with type 2 diabetes. Diabetes. 2005;54(Suppl 1):Abstract 2222-PO.Google Scholar
  35. 35.
    Chaudhry SI, Berlowitz DR, Concato J. Do age and comorbidity affect intensity of pharmacological therapy for poorly controlled diabetes mellitus? J Am Geriatr Soc. 2005;53:1214–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Naushira Pandya
    • 1
  • Andres DiGenio
    • 2
  • Ling Gao
    • 3
  • Meenakshi Patel
    • 4
  1. 1.Nova Southeastern University College of Osteopathic Medicine, Fort LauderdaleDavieUSA
  2. 2.Sanofi US, Inc.BridgewaterUSA
  3. 3.Analystat Inc.Belle MeadUSA
  4. 4.Boonshoft School of MedicineWright State UniversityDaytonUSA

Personalised recommendations